Oncolytic vaccinia virus encoding bispecific T cell adaptor and preparation method and application thereof

By carrying and expressing bispecific T cell adaptors in oncolytic vaccinia virus, the problem of tumor cell immune evasion mechanism limiting the anti-tumor effect is solved, and efficient T cell activation and killing in tumor cells is achieved, which significantly enhances lysis Anti-tumor effects and safety of tumor vaccinia virus.

CN115161293BActive Publication Date: 2024-11-15NANJING VIROTHER BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110358122.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-04-01
Publication Date
2024-11-15
Estimated Expiration
2041-04-01

AI Technical Summary

Technical Problem

The existing oncolytic vaccinia virus has not been ideal in tumor treatment. It may be that the immune evasion mechanism of tumor cells limits the activation and maintenance of tumor-specific T cells, resulting in limited therapeutic effect.

Method used

By carrying genes encoding bispecific T cell adaptors in oncolytic vaccinia virus, the virus expresses bispecific T cell adaptors in tumor cells, so that they specifically bind to tumor cell surface antigen EpCAM and T cell surface receptors CD3 mediates T cells to kill tumor cells, overcomes MHC molecules-dependent immune escape, and enhances immune response.

Benefits of technology

It significantly enhances the anti-tumor effect of oncolytic vaccinia virus, can express bispecific T cell adaptors locally in the tumor, mediates T cell targeted killing of tumors, enhances the immune response of T cells to tumor cells, and improves the multiple treatments. Anti-tumor effect and the ability to replicate selectively in tumor cells with TK-high activity improves safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115161293B_ABST
    Figure CN115161293B_ABST
Patent Text Reader

Abstract

The present invention discloses an oncolytic vaccinia virus encoding a bispecific T cell adaptor and a preparation method and application thereof, wherein the thymidine kinase region of the viral genome comprises a gene sequence encoding a bispecific T cell adaptor, one end of the bispecific T cell adaptor specifically binds to the tumor cell surface antigen EpCAM, and the other end specifically binds to the T cell surface receptor CD3. The present invention uses an oncolytic vaccinia virus to carry a bispecific T cell adaptor, and the recombinant oncolytic vaccinia virus expresses a large amount of bispecific T cell adaptors locally in the tumor, mediates T cell targeted killing of tumors, and the killing effect does not depend on MHC molecules, so it can overcome the immune escape formed by tumor cells by downregulating MHC molecules, and enhance the anti-cancer effect of oncolytic viruses; in addition, the thymidine kinase gene of the vaccinia virus genome is inactivated by the deletion of viral replication-related genes, and the virus selectively replicates in tumor cells with high thymidine kinase activity, significantly enhancing the safety of oncolytic vaccinia viruses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of gene therapy and biomedicine technology, and specifically relates to an oncolytic vaccinia virus expressing a bispecific T cell adaptor and a preparation method and application thereof. Background Art

[0002] Traditional tumor treatments including surgery, radiotherapy, chemotherapy, etc. have limited therapeutic effects and serious toxic side effects in the treatment of advanced tumors. In recent years, with the rapid development of cell biology, molecular biology and bioengineering technology, cancer immunotherapy has made major breakthroughs, among which oncolytic virus therapy has attracted widespread attention due to its outstanding effects.

[0003] Oncolytic vaccinia virus is a double-stranded DNA virus with some unique advantages: (1) Vaccinia virus can replicate rapidly in tumor cells and lyse cells; (2) It infects tumor cells by membrane fusion and does not require specific cell surface receptors, so it has a wide range of targeting to tumor cells and can infect a variety of tumor cells; (3) Vaccinia virus always exists in the cytoplasm and will not integrate into the host genome; (4) The product of virus infection of cells can be self-encapsulated, and the virus can spread over long distances through the blood flow barrier, so it has a good systemic anti-tumor effect; (5) The virus can accommodate large exogenous gene insertions; (6) Even if side effects occur during oncolytic vaccinia virus treatment, they can be controlled with commonly used antiviral drugs in clinical practice; (7) Vaccinia virus particles are relatively stable and can be freeze-dried and stored in the form of dry powder, making them easy to transport and clinically apply.

[0004] Early studies have shown that although oncolytic vaccinia virus has a high safety profile and has achieved certain therapeutic effects in clinical studies, the anti-tumor effect of oncolytic vaccinia virus is still not ideal. This may be attributed to the various immune escape mechanisms of tumor cells that limit the activation and maintenance of tumor-specific T cells. Therefore, it needs to be modified to enhance its anti-cancer effect.

[0005] Bispecific T cell engagers (BiTEs) provide a way to engage T cells with tumor cells and have shown effective therapeutic results in the clinic, such as the treatment of non-Hodgkin's lymphomas and precursor B-cell acute lymphoblastic leukemia. However, bispecific T cell engagers have a short half-life and require continuous infusion in the clinic, leading to systemic toxic side effects.

[0006] The present invention uses the oncolytic vaccinia virus WR strain as a research model and finds that the bispecific T cell engager carrying the tumor antigen and effector cell targeting can significantly enhance the anti-tumor effect of the oncolytic vaccinia virus. The present invention will focus on the preparation method of oncolytic vaccinia virus expressing the bispecific T cell engager and its application. Summary of the invention

[0007] In view of the problems in the prior art that although oncolytic vaccinia viruses can induce effective infiltration of T cells in tumor tissues, various immune escape mechanisms of tumor cells limit the activation of tumor-specific T cells, thereby reducing the anti-tumor effect of oncolytic vaccinia viruses, the first object of the present invention is to provide an oncolytic vaccinia virus encoding a bispecific T cell engager; the second object of the present invention is to provide a method for preparing an oncolytic vaccinia virus encoding a bispecific T cell engager; and the third object of the present invention is to provide an application of an oncolytic vaccinia virus encoding a bispecific T cell engager.

[0008] This application has the following technical solutions:

[0009] A oncolytic vaccinia virus encoding a bispecific T cell engager, wherein the thymidine kinase (TK) region of the viral genome comprises a gene sequence encoding the bispecific T cell engager and is capable of infecting tumor cells to cause them to express the bispecific T cell engager.

[0010] Among them, one end of the bispecific T cell engager specifically binds to the tumor cell surface antigen EpCAM, and the other end specifically binds to the T cell surface receptor CD3. The oncolytic vaccinia virus can infect tumor cells to make them express the bispecific T cell engager.

[0011] By carrying a bispecific T cell engager in the oncolytic vaccinia virus, the virus can express a large amount of bispecific T cell engagers locally in the tumor, mediate the targeted killing of tumors by T cells, and this killing effect is independent of MHC molecules. Therefore, it can overcome the immune escape of tumor cells by downregulating MHC molecules, enhance the immune response of T cells to tumor cells, and inhibit the exhaustion of activated T cells, thereby exerting multiple anti-tumor effects.

[0012] As a preferred technical solution of the present application, the bispecific T cell engager is composed of a single-chain antibody (scFv) that specifically recognizes the tumor-associated antigen EpCAM, a linker polypeptide, and a single-chain antibody (scFv) that specifically binds to the T cell surface receptor CD3, and its nucleotide sequence is shown in SEQ ID NO.1.

[0013] As a preferred technical solution of the present application, the amino acid sequence of the light chain variable region of the single-chain antibody that specifically recognizes the tumor-associated antigen EpCAM is shown in SEQ ID NO.2.

[0014] As a preferred technical solution of the present application, the amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically recognizes the tumor-associated antigen EpCAM is shown in SEQ ID NO.3.

[0015] As a preferred technical solution of the present application, the amino acid sequence of the light chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.4.

[0016] As a preferred technical solution of the present application, the amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.5.

[0017] As a preferred technical solution of the present application, the linker polypeptide is GGGGS.

[0018] The oncolytic vaccinia virus is capable of lysing tumor cells.

[0019] One end of the bispecific T cell adaptor expressed by the oncolytic vaccinia virus can specifically bind to the tumor cell surface antigen EpCAM, and the other end can specifically bind to the T cell surface antigen CD3.

[0020] The method for preparing an oncolytic vaccinia virus encoding a bispecific T cell adaptor comprises the following steps:

[0021] (1) adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence, respectively, and then artificially synthesizing the above sequences;

[0022] (2) The synthesized gene fragment was double-digested with EcoR1 and Xba1 and then subcloned into the restriction sites corresponding to the shuttle plasmid pVV-Control to construct the pVV-EpCAM-BiTE plasmid; wherein the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L;

[0023] (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid was used to transfect cells that had been pre-infected with wild vaccinia virus (WR strain), so that the plasmid and wild vaccinia virus underwent homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

[0024] As a preferred technical solution of the present application, the bispecific T cell engager gene sequence is SEQ ID NO.1.

[0025] The present invention also protects the use of the above-mentioned oncolytic vaccinia virus encoding the bispecific T cell adaptor in the preparation of related drugs for treating or preventing tumors.

[0026] Preferably, the tumor is selected from any one of breast cancer, colorectal cancer, liver cancer, melanoma, lung cancer, gastric cancer, pancreatic cancer, gallbladder cancer, kidney cancer, bladder cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, head and neck cancer, glioma, cancerous ascites, and cancerous pleural effusion;

[0027] More preferably, the tumor is breast cancer or colon cancer.

[0028] Beneficial Effects

[0029] Compared with the prior art, the oncolytic vaccinia virus of the present invention can exert the following anti-tumor effects:

[0030] (1) The present invention effectively combines the oncolytic effect of oncolytic vaccinia virus with the anti-tumor effect of bispecific T cell adaptor, and prepares an oncolytic vaccinia virus that can express bispecific T cell adaptor. On the one hand, the virus can replicate in tumor cells and exert an oncolytic effect; on the other hand, the virus can effectively induce T cell infiltration, transforming the "cold" tumor microenvironment into a "hot" tumor microenvironment. The virus can infect tumor cells and cause them to express bispecific T cell adaptors, one end of which specifically binds to the tumor cell surface antigen EpCAM and the other end specifically binds to the T cell surface receptor CD3, mediating T cell targeted killing of tumor cells, and the killing effect is independent of MHC molecules, so it can overcome the immune escape formed by tumor cells by downregulating MHC molecules, enhance the immune response of T cells to tumor cells, and thus exert multiple anti-tumor effects.

[0031] (2) Inserting a bispecific T cell adaptor gene into the TK region of the vaccinia virus genome results in the inactivation of the TK gene on which the virus replication depends, allowing the virus to selectively replicate in tumor cells with high TK activity, significantly enhancing the safety of oncolytic vaccinia virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 This is a schematic diagram of oncolytic vaccinia virus VV-EpCAM-BiTE.

[0033] Figure 2 It is a map of the vaccinia virus shuttle plasmid pVV-EpCAM-BiTE.

[0034] Figure 3 Virus plaques are produced by HELA-S3 cells infected with oncolytic vaccinia virus VV-EpCAM-BiTE.

[0035] Figure 4 The Western Blot method was used to detect the expression of bispecific T cell engagers in the culture supernatant of HELA-S3 cells infected with oncolytic vaccinia virus VV-EpCAM-BiTE. As can be seen from the figure, the molecular weight of the bispecific T cell engager is about 70KD.

[0036] Figure 5 Flow cytometry was used to detect the blocking effect of bispecific T cell adaptors secreted by tumor cells infected with oncolytic vaccinia virus VV-EpCAM-BiTE on EpCAM on the surface of breast cancer cell line 4T1.

[0037] Figure 6 The MTT assay was used to detect the in vitro oncolytic ability of oncolytic vaccinia virus VV-EpCAM-BiTE on breast cancer cell line 4T1, colon cancer cell line CT26 and melanoma cell line B16 / F10. As can be seen from the figure, the oncolytic ability of VV-EpCAM-BiTE gradually increased with the increase of the multiplicity of infection (MOI).

[0038] Figure 7 The plaque assay was used to detect the in vitro viral replication of oncolytic vaccinia virus VV-EpCAM-BiTE in breast cancer cell line 4T1, colon cancer cell line CT26 and melanoma cell line B16 / F10.

[0039] Figure 8 The therapeutic effect of intratumoral injection of oncolytic vaccinia virus VV-EpCAM-BiTE on the EpCAM-expressing breast cancer 4T1 subcutaneous transplant tumor model. As can be seen from the figure, compared with PBS and the control virus VV-Control, VV-EpCAM-BiTE can significantly inhibit the growth of 4T1 subcutaneous transplant tumors and prolong the survival time of mice.

[0040] Fig. 9 Intratumoral injection of oncolytic vaccinia virus VV-EpCAM-BiTE is effective in the treatment of MC38-EpCAM in colon cancer + The therapeutic effect of subcutaneous transplant tumor model. As shown in the figure, compared with PBS and control virus VV-Control, VV-EpCAM-BiTE can significantly inhibit MC38-EpCAM + The growth of subcutaneous transplanted tumors and prolonged the survival of mice. DETAILED DESCRIPTION

[0041] The present invention is further described in conjunction with the following examples. Unless otherwise specified, the present invention can adopt conventional techniques in the art, and the scope of the present invention is not limited by these examples.

[0042] Example 1: Construction of shuttle plasmid pVV-EpCAM-BiTE

[0043] The nuclease EcoR1 recognition sequence GAATTC and the Kozak sequence GCCACC were added to the front end of the bispecific T cell adaptor gene sequence (SEQ ID NO.1), and the nuclease Xba1 recognition sequence TCTAGA was added to the end. Then, the above sequence was synthesized by Nanjing GenScript Company using an artificial synthesis method and subcloned into the restriction sites EcoR1 and Xba1 corresponding to the pVV-Control plasmid (SEQ ID NO.4 disclosed in patent CN202010790895.9). The newly synthesized plasmid was named pVV-EpCAM-BiTE, and its plasmid map is shown in Figure 2 shown.

[0044] Example 2: Oncolytic Vaccinia Virus Packaging and Screening

[0045] HEK293 cells were routinely cultured in DMED high-glucose medium containing 10% FBS, and the cells were digested with 0.5% trypsin and counted at 3 × 10 5 cells / well were inoculated into 6-well plates and cultured in a 37°C, 5% CO2 incubator. When the cells grew to a confluency of more than 90%, wild vaccinia virus (WR strain, purchased from ATCC, accession number: VR-1354) were infected for 2 hours (MOI = 1). The HEK293 cells pre-infected with wild vaccinia virus were transfected with a transfection reagent (Polyplus-transfection Company). The transfected HEK293 cells were cultured in a 37°C, 5% CO2 incubator to allow homologous recombination between the plasmid and wild vaccinia virus to occur, producing oncolytic vaccinia virus VV-EpCAM-BiTE, as shown in the schematic diagram. Figure 1 As shown. The oncolytic vaccinia virus VV-EpCAM-BiTE inserts the guanine-hypoxanthine phosphoribosyltransferase (GPT) gene and the fluorescent protein reporter gene (EGFP) into the TK region of the wild virus. The two are connected by 2A peptide, and their expression is controlled by the p7.5K promoter; the expression of the inserted bispecific T cell adaptor gene is controlled by the vaccinia virus early and late promoter pSE / L, and its gene sequence is shown in SEQ ID NO.1. The packaging of the control virus VV-Control is similar to that of VV-EpCAM-BiTE, and is obtained by homologous recombination between the pVV-Control plasmid and the wild vaccinia virus.

[0046] Plaque purification was used to screen oncolytic vaccinia viruses. After 48 hours of transfection, oncolytic vaccinia viruses produced plaques (such as Figure 3As shown in Figure 2, wild virus was removed by plaque purification under the condition of screening medium containing 25 μg / ml mycophenolic acid (MPA), 250 μg / ml xanthine and 15 μg / ml hypoxanthine, and vaccinia virus VV-Control and VV-EpCAM-BiTE without wild virus were obtained. Then, the genome of oncolytic vaccinia virus was extracted by virus genome extraction kit (Kangwei Century Company), and the target gene and wild virus thymidine kinase (TK) gene were amplified by the following primers, respectively, and the amplification conditions were 98°C for 3 minutes, 98°C for 10 seconds, 55°C for 5 seconds, 72°C for 20 seconds, 30 cycles, and 72°C for 5 minutes. Target gene: 5'-caggtgatctgtttttattgtggag-3', 5'-gatctacttccttaccgtgc-3'; TK: 5'-tgtgaagacgataaattaatgatc-3', 5'-gtttgccatacgctcacag-3'. The virus that successfully amplified the target gene by PCR but did not simultaneously amplify the wild virus TK gene was a successfully screened oncolytic vaccinia virus. The successfully screened oncolytic vaccinia virus was further amplified in a cell culture dish using HELA-S3 cells. The titer of the virus was determined by the TCID50 method, and the calculation formula was as follows: virus titer = 0.7 × 10 × 10^(1 + S (D-0.5)), where S = log10 (dilution), D = the sum of the EGFP positive ratios of each dilution.

[0047] Example 3: Oncolytic vaccinia virus secretion of bispecific T cell engagers and their functional identification

[0048] HELA-S3 cells were cultured in DMED high-glucose medium containing 10% FBS, and the cells were digested with 0.5% trypsin and counted. 5 Cells / well were inoculated in a 6-well plate and cultured in a 37°C, 5% CO2 incubator. When the cells grew to a confluency of more than 90%, oncolytic vaccinia virus was added for infection (MOI = 0.1). After 48 hours, the cell culture supernatant was collected, and the expression of bispecific T cell adaptors in the cell culture supernatant was detected by Western Blot using anti-FLAG tag antibody as the first antibody. Figure 4 As shown, HELA-S3 cells infected with oncolytic vaccinia virus VV-EpCAM-BiTE can secrete bispecific T cell engagers in the cell culture supernatant with a molecular weight of approximately 70KD.

[0049] 2×10 54T1 breast cancer cells were incubated with 100 μl of cell culture supernatant infected with VV-EpCAM-BiTE or VV-Control at room temperature. After 20 minutes, 1 ml of PBS was added to mix, and the mixture was centrifuged at 1000 rpm / min for 5 minutes. The supernatant was removed and the cells were resuspended with 100 μl of PBS. 4T1 cells were labeled with Isotype-PE and EpCAM-PE monoclonal antibodies (eBioscience) respectively. The cells were incubated at room temperature in the dark for 15 minutes, and 4% paraformaldehyde was added to fix the cells. FACS Calibur flow cytometer (BD) was used for detection, and FlowJo software was used for data analysis. Figure 5 As shown, after 4T1 cells were incubated with the cell supernatant containing secreted bispecific T cell engagers, the peak of EpCAM expression shifted forward, suggesting that VV-EpCAM-BiTE can express bispecific T cell engagers and bind to and block EpCAM molecules on the surface of 4T1 cells.

[0050] Example 4: In vitro oncolytic ability of oncolytic vaccinia virus on tumor cells

[0051] The MTT assay was used to quantitatively analyze the oncolytic ability of oncolytic vaccinia virus on tumor cells. Breast cancer cells 4T1, colon cancer cells CT26, and melanoma cells B16 / F10 were cultured in DMED high-glucose medium containing 10% FBS, and the cells were digested with 0.5% trypsin and counted. 4 Cells / well were inoculated in a 96-well plate and cultured in a 37°C, 5% CO2 incubator. When the cells grew to a confluency of more than 90%, oncolytic vaccinia viruses with different infection multiplicity (0, 0.1, 1, 5, 10) were added. After 72 hours of culture, 20 μl of thiazolyl blue (MTT) was added to each well and culture continued. After 4 hours, the supernatant was removed and 150 μl of isopropanol was added to dissolve formazan. The absorbance (OD) value was detected at 570 nm by a microplate reader, and the cell viability was calculated according to the following formula: Cell viability (%) = (experimental well-blank control well) / (control well-blank control group) × 100%. Figure 6 As shown, with the increase of the multiplicity of infection (MOI), the oncolytic ability of VV-EpCAM-BiTE on 4T1, CT26 and B16 / F10 cells gradually increased.

[0052] Example 5: Replication ability of oncolytic vaccinia virus in tumor cells

[0053] Breast cancer cell 4T1, colon cancer cell CT26 and melanoma cell B16 / F10 were cultured in DMED high-glucose medium containing 10% FBS, and the cells were digested with 0.5% trypsin and counted.5 Cells / well were inoculated in a 24-well plate and cultured in a 37°C, 5% CO2 incubator. After 24 hours, oncolytic vaccinia virus with a multiplicity of infection of 0.1 was added. After the cells were infected with the virus for 24, 48, 72, and 96 hours, the TCID50 method was used to detect the replication ability of the virus. Figure 7 As shown, VV-EpCAM-BiTE oncolytic vaccinia virus can replicate in all these cells. In 4T1 and B16 / F10 cells, the virus titer reaches the peak at 48 hours. In CT26 cells, the virus titer reaches the peak at 72 hours.

[0054] Example 6: Therapeutic effect of oncolytic vaccinia virus on subcutaneous transplanted breast cancer tumors

[0055] In this example, 4T1 breast cancer cells were first cultured in DMED high-glucose medium containing 10% FBS, and then the cells were digested with 0.5% trypsin and the cells were counted. 1×10 6 The cells were labeled with Isotype-PE and EpCAM-PE monoclonal antibodies (eBioscience) respectively. The cells were incubated at room temperature in the dark for 15 minutes, and 4% paraformaldehyde was added to fix the cells. The FACS Calibur flow cytometer (BD) was used for detection, and FlowJo software was used for data analysis. Figure 8 As shown, EpCAM is highly expressed on the surface of 4T1 breast cancer cell line.

[0056] 4T1 cells were used to establish a breast cancer subcutaneous tumor model. Female BALBIC mice aged 6-8 weeks (SPF grade, purchased from the Model Animal Research Institute of Nanjing University) were selected and injected subcutaneously with 2×10 5 4T1 cells. About 6 days after modeling, when the tumor diameter grew to about 5 mm, the mice were randomly divided into 3 groups, namely PBS control group, VV-Control and VV-EpCAM-BiTE treatment groups, and PBS, VV-Control and VV-EpCAM-BiTE were injected into the tumor at multiple sites for treatment. The dose of virus injection was 1×10 7 PFU, treatment was performed once every 2 days for a total of 3 times. After the first viral treatment, the long and short diameters of the tumor were measured every 2 days, and the mice were weighed. The tumor volume was calculated using the following formula: Tumor volume = 1 / 2 × long diameter (mm) × short diameter (mm) 2 Calculate the tumor volume. When the tumor volume is greater than 2000mm 3 When the mouse is judged to be dead. Figure 8As shown in the figure, compared with PBS and VV-Control, VV-EpCAM-BiTE can significantly inhibit the growth of 4T1 subcutaneous transplanted tumors and prolong the survival time of mice. There was no significant difference in the weight of mice among the three groups, indicating that intratumoral injection of oncolytic vaccinia virus VV-EpCAM-BiTE has no obvious toxic side effects on BALB / c mice.

[0057] Example 7: Therapeutic effect of oncolytic vaccinia virus on subcutaneous transplanted colon cancer tumors

[0058] In this example, MC38-EpCAM overexpressing colon cancer cells were used. + MC38-EpCAM was first identified by flow cytometry. + The expression of EpCAM on the cell surface, such as Fig. 9 As shown, EpCAM is expressed in MC38-EpCAM + Highly expressed on the cell surface.

[0059] Then, 6-8 week-old male C57BL / 6 mice (SPF grade, purchased from the Model Animal Institute of Nanjing University) were selected and injected subcutaneously with 2×10 6 MC38-EpCAM + Cells. About 4 days after modeling, when the tumor diameter grew to about 5 mm, the mice were randomly divided into 3 groups, namely, PBS control group, VV-Control control group and VV-EpCAM-BiTE treatment group. The treatment dose, treatment method and detection index were the same as those in Example 7. Fig. 9 As shown in Figure 2, compared with PBS and the control virus VV-Control, VV-EpCAM-BiTE can significantly inhibit MC38-EpCAM + The growth of subcutaneous transplanted tumors. At the same time, VV-EpCAM-BiTE treatment significantly prolonged the survival time of tumor-bearing mice. There was no significant difference in the body weight of mice between the PBS, VV-Control and VV-EpCAM-BiTE treatment groups, indicating that intratumoral injection of oncolytic vaccinia virus VV-EpCAM-BiTE treatment had no obvious toxic side effects on C57BL / 6 mice.

[0060] Those skilled in the art should understand that the present invention is not limited to the above-mentioned embodiments. The above-mentioned embodiments and descriptions are only for explaining the principles of the present invention. Various changes and improvements may be made to the present invention without departing from the spirit and scope of the present invention. The scope of protection required by the present invention is defined by the attached claims, description and their equivalents. Sequence Listing <110> Nanjing Weiyade Biopharmaceutical Co., Ltd. <120> Oncolytic vaccinia virus encoding bispecific T cell adaptor and preparation method and application thereof <160> 5 <170> SIPOSequenceListing 1.0 <210> 1 <211> 1542 <212> DNA <213> Artificial Sequence <400> 1 atggacatcc ggctgagcct ggccttcctg gtgctgttta tcaagggcgt gcagtgcgag 60 gtgcagctgg ctgagtccgg aggaggcctg gtgcagccag gcaggtccat gaagctgtct 120 tgtgccgcta gcggattcac ctttagcaac ttccccatgg cctgggtgag acaggctcct 180 acaaagtgcc tggagtgggt ggccaccatc tccacatctg gaggcagcac ctactaccgg 240 gactccgtga agggcaggtt taccatcagc agggataacg ccaagagcac actgtacctg 300 cagatgaaca gcctgcgctc cgaggacacc gctacatact actgtacccg gacactgtac 360 atcctgcgcg tgttctactt tgattactgg ggccagggag tgatggtgac agtgagctcc 420 ggaggaggag gatccggcgg aggaggctct ggaggcggag gcagcgacat ccagatgacc 480 cagtccccag ctagcctgtc cgcttctctg ggagagacag tgtctatcga gtgcctggcc 540 tccgagggaa tctctaacga cctggcttgg taccagcaga agtctggcaa gagcccacag 600 ctgctgatct acgccacctc taggctccag gatggagtgc ccagcagatt cagcggctcc 660 ggatctggca caagatacag cctgaagatc tccggcatgc agcctgagga cgaggctgat 720 tacttctgcc agcagtccta caagtaccca tggacctttg gatgtggcac aaagctgggag 780 ctgaagggag gaggaggatc cgaggtgcag ctggtggagt ctggaggagg actggtgcag 840 cctggcaagt ctctgaagct gagctgtgag gcctccggat tcacctttag cggatacggc 900 atgcactggg tgcggcaggc tcctggaagg ggcctggagt ccgtggctta catcacctct 960 agctccatca acatcaagta cgccgacgct gtgaagggca ggttcaccgt gagcagggac 1020 aatgccaaga acctgctgtt tctgcagatg aatatcctga agtccgagga caccgccatg 1080 tactactgtg ctaggttcga ctgggataag aactactggg gacagggcac catggtgaca 1140 gtgtcttctg gcggcggcgg atccggagga ggaggatctg gcggaggcgg aagcgatatc 1200 cagatgaccc agagcccatc ctctctgcct gcttccctgg gcgacagagt gacaatcaac 1260 tgccaggctt ctcaggatat cagcaactac ctgaactggt accagcagaa gccaggcaag 1320 gcccccaagc tgctgatcta ctacaccaac aagctggctg acggagtgcc aagccggttc 1380 agcggatccg gatctggaag ggacagctcc tttacaatct ctagcctgga gtccgaggat 1440 atcggctctt actactgcca gcagtactac aactaccctt ggacctttgg cccaggaaca 1500 aagctggaga tcaaggatta caaggacgat gacgataagt aa 1542 <210> 2 <211> 121 <212> PRT <213> Artificial Sequence <400> 2 Glu Val Gln Leu Ala Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Arg 1 5 10 15 Ser Met Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Phe 20 25 30 Pro Met Ala Trp Val Arg Gln Ala Pro Thr Lys Cys Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Thr Ser Gly Gly Ser Thr Tyr Tyr Arg Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ser Glu Asp Thr Ala Thr Tyr Tyr Cys 85 90 95 Thr Arg Thr Leu Tyr Ile Leu Arg Val Phe Tyr Phe Asp Tyr Trp Gly 100 105 110 Gln Gly Val Met Val Thr Val Ser Ser 115 120 <210> 3 <211> 107 <212> PRT <213> Artificial Sequence <400> 3 Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Thr Val Ser Ile Glu Cys Leu Ala Ser Glu Gly Ile Ser Asn Asp 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Ser Gly Lys Ser Pro Gln Leu Leu Ile 35 40 45 Tyr Ala Thr Ser Arg Leu Gln Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Arg Tyr Ser Leu Lys Ile Ser Gly Met Gln Pro 65 70 75 80 Glu Asp Glu Ala Asp Tyr Phe Cys Gln Gln Ser Tyr Lys Tyr Pro Trp 85 90 95 Thr Phe Gly Cys Gly Thr Lys Leu Glu Leu Lys 100 105 <210> 4 <211> 116 <212> PRT <213> Artificial Sequence <400> 4 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Lys 1 5 10 15 Ser Leu Lys Leu Ser Cys Glu Ala Ser Gly Phe Thr Phe Ser Gly Tyr 20 25 30 Gly Met His Trp Val Arg Gln Ala Pro Gly Arg Gly Leu Glu Ser Val 35 40 45 Ala Tyr Ile Thr Ser Ser Ser Ile Asn Ile Lys Tyr Ala Asp Ala Val 50 55 60 Lys Gly Arg Phe Thr Val Ser Arg Asp Asn Ala Lys Asn Leu Leu Phe 65 70 75 80 Leu Gln Met Asn Ile Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Phe Asp Trp Asp Lys Asn Tyr Trp Gly Gln Gly Thr Met Val 100 105 110 Thr Val Ser Ser 115 <210> 5 <211> 107 <212> PRT <213> Artificial Sequence <400> 5 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Pro Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Asn Cys Gln Ala Ser Gln Asp Ile Ser Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Thr Asn Lys Leu Ala Asp Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Arg Asp Ser Ser Phe Thr Ile Ser Ser Leu Glu Ser 65 70 75 80 Glu Asp Ile Gly Ser Tyr Tyr Cys Gln Gln Tyr Tyr Asn Tyr Pro Trp 85 90 95 Thr Phe Gly Pro Gly Thr Lys Leu Glu Ile Lys 100 105

Claims

1. An oncolytic vaccinia virus encoding a bispecific T cell engager, It is characterized in that The thymidine kinase region of the viral genome contains a gene sequence encoding a bispecific T cell engager, the sequence of which is shown in SEQ ID NO.1, and can infect tumor cells to make them express the bispecific T cell engager; one end of the bispecific T cell engager can specifically bind to the tumor antigen EpCAM, and the other end can specifically bind to the T cell surface receptor CD3; the bispecific T cell engager is composed of a single-chain antibody that specifically recognizes the tumor-associated antigen EpCAM, a linker polypeptide, and a single-chain antibody that specifically binds to the T cell surface receptor CD3; the linker polypeptide is GGGGS.

2. The oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 1, It is characterized in that The amino acid sequence of the light chain variable region of the single-chain antibody that specifically recognizes the tumor-associated antigen EpCAM is shown in SEQ ID NO.

2.

3. An oncolytic vaccinia virus encoding a bispecific T cell engager according to any one of claims 1 or 2, It is characterized in that The amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically recognizes the tumor-associated antigen EpCAM is shown in SEQ ID NO.

3.

4. An oncolytic vaccinia virus encoding a bispecific T cell engager according to any one of claims 1 or 2, It is characterized in that The amino acid sequence of the light chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

4.

5. The oncolytic vaccinia virus encoding a bispecific T cell engager according to any one of claims 3, It is characterized in that The amino acid sequence of the light chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

4.

6. An oncolytic vaccinia virus encoding a bispecific T cell engager according to any one of claims 1 or 2, It is characterized in that The amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

5.

7. The oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 3, It is characterized in that The amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

5.

8. The oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 4, It is characterized in that The amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

5.

9. The oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 5, It is characterized in that The amino acid sequence of the heavy chain variable region of the single-chain antibody that specifically binds to the T cell surface receptor CD3 is shown in SEQ ID NO.

5.

10. A method for preparing an oncolytic vaccinia virus encoding a bispecific T cell engager according to any one of claims 1 or 2, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

11. A method for preparing an oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 3, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

12. A method for preparing an oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 4, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

13. A method for preparing the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 5, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

14. A method for preparing an oncolytic vaccinia virus encoding a bispecific T cell engager according to claim 6, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

15. A method for preparing the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 7, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

16. A method for preparing the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 8, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

17. A method for preparing the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 9, It is characterized in that The following steps are involved: (1) Adding the EcoR1 recognition sequence GAATTC, the Kozak sequence GCCACC, and the Xba1 recognition sequence TCTAGA before and after the bispecific T cell engager gene sequence SEQ ID NO.1, respectively, and artificially synthesizing the above sequences; (2) The gene fragment synthesized in step (1) was subcloned into the restriction site corresponding to the shuttle plasmid pVV-Control using EcoR1 and Xba1 double restriction enzymes to construct the pVV-EpCAM-BiTE plasmid; the expression of the bispecific T cell adaptor was controlled by the vaccinia virus early and late promoter pSE / L; (3) Using gene homologous recombination, the pVV-EpCAM-BiTE plasmid is used to transfect cells that have been pre-infected with wild vaccinia virus, so that the plasmid and wild vaccinia virus undergo homologous recombination to produce recombinant oncolytic vaccinia virus VV-EpCAM-BiTE.

18. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to any one of claims 1 or 2 in the preparation of drugs related to the treatment or prevention of tumors, wherein the tumor is breast cancer or colon cancer.

19. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 3 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

20. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 4 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

21. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 5 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

22. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 6 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

23. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 7 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

24. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 8 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.

25. Use of the oncolytic vaccinia virus encoding the bispecific T cell engager according to claim 9 in the preparation of relevant drugs for treating or preventing tumors, wherein the tumor is breast cancer or colon cancer.